QCG
PTCT icon

Quadrant Capital Group’s PTC Therapeutics PTCT Stock Holding History

Quadrant Capital Group’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-275
Closed -$18.7K – 2240
2026
Q1 		$18.7K Buy
275
+208
+310% +$14.7K ﹤0.01% 2015
2025
Q4 		$5.09K Buy
+67
New +$4.87K ﹤0.01% 2373
2023
Q3 		– Sell
-4
Closed -$163 – 2754
2023
Q2 		$163 Hold
4
– – ﹤0.01% 2666
2023
Q1 		$194 Hold
4
– – ﹤0.01% 2677
2022
Q4 		$153 Buy
+4
New +$166 ﹤0.01% 2708
2022
Q2 		– Sell
-3
Closed – – 2687
2022
Q1 		$0 Sell
3
-15
-83% -$578 ﹤0.01% 2658
2021
Q4 		$1K Sell
18
-108
-86% -$4.13K ﹤0.01% 2382
2021
Q3 		$5K Buy
126
+98
+350% +$4.03K ﹤0.01% 1884
2021
Q2 		$1K Sell
28
-39
-58% -$1.67K ﹤0.01% 2307
2021
Q1 		$3K Buy
67
+53
+379% +$3.15K ﹤0.01% 1977
2020
Q4 		$1K Buy
14
+8
+133% +$472 ﹤0.01% 2176
2020
Q3 		$0 Buy
+6
New +$295 ﹤0.01% 2276
2020
Q2 		– Sell
-4
Closed – – 2360
2020
Q1 		$0 Buy
+4
New +$201 ﹤0.01% 2233
2016
Q2 		– Sell
-203
Closed -$1K – 2056
2016
Q1 		$1K Buy
+203
New +$3.52K ﹤0.01% 1571

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Quadrant Capital Group's PTCT Position: Q2 2026 in Review

Quadrant Capital Group sold out of PTC Therapeutics (PTCT) in Q2 2026, closing a stake of 275 shares — an estimated $18.7K sold.

Quadrant Capital Group first reported a position in PTCT in Q1 2016 and held it in 14 quarters. The position peaked at $18.7K in Q1 2026. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Quadrant Capital Group reported no remaining PTC Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 275 PTC Therapeutics shares in Q2 2026, an estimated $18.7K.
  • Quadrant Capital Group first reported a position in PTC Therapeutics in Q1 2016 and held it in 14 quarters.
  • Quadrant Capital Group's PTC Therapeutics position peaked at $18.7K in Q1 2026.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.